IPP Bureau
WHO unveils updated HIV guidelines to boost treatment & save lives
By IPP Bureau - January 09, 2026
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy
By IPP Bureau - January 09, 2026
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer
By IPP Bureau - January 09, 2026
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
By IPP Bureau - January 09, 2026
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
World First: Heart bypass without opening the chest achieved by NIH and Emory Team
By IPP Bureau - January 09, 2026
Addex spin-out Neurosterix launches Phase 1 trial for novel schizophrenia drug
By IPP Bureau - January 09, 2026
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Newron secures key European patent for schizophrenia drug Evenamide
By IPP Bureau - January 09, 2026
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity
By IPP Bureau - January 09, 2026
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids
By IPP Bureau - January 09, 2026
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Lilly to buy Ventyx Biosciences for $1.2 billion
By IPP Bureau - January 08, 2026
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal
By IPP Bureau - January 08, 2026
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity
By IPP Bureau - January 08, 2026
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
GSK’s Exdensur wins Japanese nod for severe asthma
By IPP Bureau - January 08, 2026
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer
By IPP Bureau - January 08, 2026
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
By IPP Bureau - January 08, 2026
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
